PHOENIX, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Premier Biomedical Inc., (OTC:BIEI) President & CEO, William A. Hartman today reviewed operational accomplishments of 2017 and expectations for 2018 in an interview on Uptick Newswire’s “Stock Day” podcast with Everett Jolly.
Premier Biomedical consists of two divisions, one focused on biologics and the other on topical pain relief products. The pain relief division is revenue generating and has grown from one product a year ago, to five products today, distributed through the company’s website, www.painreliefmeds.com, and by a number of regional pharmacies and an on-line pharmacy, HealthWarehouse.com.
“You have had impressive results from your cancer research,” said Jolly. “Results that have been published by the American Association for Cancer Research as well as the British Journal of Cancer. The company has also been able to grow the pain relief division significantly in only a year.”
“We are proud of the work we have done in cancer research. Recently, our Biologics Division has also focused on anti-aging, an industry worth over $1 billion in the United States alone,” Hartman commented. “We are very optimistic regarding our work with anti-aging. We have proven the ability to remove specific antigens from blood and have identified the antigens linked to aging. We will continue to pursue this avenue, which has an incredible upside.”
“On the pain relief front, we have made great strides in developing new, and highly effective products in 2017, and will concentrate on marketing and sales in 2018.”
To listen to the full interview please click here to the following link: https://upticknewswire.com/featured-interview-ceo-william-hartman-of-premier-biomedical-inc-otcqb-biei-4
About Premier Biomedical Inc.
Premier Biomedical, Inc. has acquired exclusive licenses for patent-pending medications/medical procedures to develop cures for a significant number of the most debilitating and often fatal illnesses affecting mankind: Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI), Multiple Sclerosis (MS), Clinical Depression, Alzheimer’s Disease, Blood Sepsis, Atherosclerosis, Cancer and Anti-aging. We have developed an aggressive timetable to advance the development of these breakthrough technologies through laboratory, hospital, and clinical trials. We have a management team with extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment. Our extensive contacts in the medical/pharmaceutical industries will ensure that new developments will achieve maximum visibility and exposure to the market. Transparency and accountability will continue to be ensured via regular issuance of technical progress reports, financials, and investor relations reports to maintain investor enthusiasm.
About Uptick Newswire and the “Stock Day Podcast”
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick
Follow us and keep an eye on Uptick’s YouTube, Twitter, and Facebook for additional radio and video shows produced by Uptick! https://www.youtube.com/watch?v=kU5SVLp4org
Investors Hangout is a proud sponsor of Stock Day and Uptick Newswire encourages listeners to visit Premier Biomedical’s message board on: https://investorshangout.com/Premier-Biomedical-Inc-BIEI-88326/
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
For further information please contact:
William A. Hartman
President and CEO
Premier Biomedical Inc.
(724) 633-7033
w.hartman@premierbiomedical.com
www.premierbiomedical.com
Source: Uptick Newswire